Article on anti-tumor activity of PV-10 against relapsed and refractory neuroblastoma published in OncoTargets and Therapy
February 19, 2019 07:30 ET
|
Provectus Biopharmaceuticals Inc.
Provides preclinical proof-of-concept data on efficacy of single-agent PV-10 for treatment of neuroblastomaSupports use of checkpoint inhibitors with PV-10 treatment backbone to further enhance...